TSHR
Thyrotropin receptor
As of the edition of 20 October 2026, TSHR (thyrotropin receptor, UniProt P16473) has 2 drugs tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16473
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 9
- Disease areas
- Hormones; Cancer; Blood and lymph; Eye; Heart and blood vessels; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Thyrotropin alfa | Marketed | Phase 4 | Ended 2014 |
| Thyrotropin | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |